Identity and synonyms
Catalog label is recorded; analytical identity and equivalence are not established.
Nonpeptide agent · Nonpeptide small molecule
Detailed molecular class: Nonpeptide agent; see mechanism for subtype
Supplied sequence or chemical reference
PubChem CID: 892
Molecular formula: C6H12O6
IUPAC: cyclohexane-1,2,3,4,5,6-hexol
Source: PC-INOSITOL
Database chemical reference; does not certify supplier vial, salt, isomer or formulation.
Mechanism
Nonpeptide polyol; myo-inositol and D-chiro-inositol are isomers with different signaling roles.
Evidence and critical reading
Reported scientific and empirical uses
Replacement and nutritional context
Studied in PCOS and incorporated into MIC blends; an “inositol” label does not establish isomer/ratio.
Human evidence
A 464-pregnant-PCOS-participant trial did not reduce the composite complication outcome with myo-inositol versus a folate control. Neither negative nor positive findings generalize to every context.
Preclinical evidence
Do not equate mechanism, cell culture or animal work with a clinical outcome. The specific level is detailed in the evidence assessment.
Critical reading and limitations
A 464-pregnant-PCOS-participant trial did not reduce the composite complication outcome with myo-inositol versus a folate control. Neither negative nor positive findings generalize to every context.
A 464-pregnant-PCOS-participant trial did not reduce the composite complication outcome with myo-inositol versus a folate control. Neither negative nor positive findings generalize to every context.
Source-specific regimens
Descriptive source observations, not individual recommendations.
Regulatory product labeling
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Human-study exposure
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Reported by Myo-inositol Supplementation to Prevent Pregnancy Complications in Polycystic Ovary Syndrome: A Randomized Clinical Trial.
2 g · Per administration; component studied with folate
- Frequency
- Twice/day
- Duration
- During pregnancy until delivery per trial
- Route
- Oral
- Context
- 464 pregnant PCOS participants; folate in both groups, no complication reduction.
- Presentation
- A dosage-form presentation is not specified in the reviewed record.
- Interpretation
- Research exposure: not a prescription or starting regimen. It does not reconstruct protocol titration, exclusions or monitoring.
PMID40920401 · October 16, 2026
NOT A RECOMMENDATION.Each amount is attributed to the source identified for that entry: regulatory product labeling, human research, or community and practice sources. These source categories have different evidentiary roles. They are not medical advice, not a protocol, not a recommended or safe dose, and not evidence that it works. Do not use them to start, change or stop any treatment. Talk to a qualified healthcare professional.
Empirical handbook
Listed regimens preserve source/context. An empty layer means no regimen attributable to this identity was verified in this review; it does not prove universal absence of data.
Regulation and safety
Jurisdiction-specific regulatory context
This record does not verify FDA/EMA authorization of the commercial identity. Where a specific medicine/product exists, jurisdiction/indication are detailed in cited sources; they do not transfer to supplier material.
Adverse effects and unknowns
Oral evidence does not validate MIC injection or all isomers. Pregnancy requires an evaluated indication/formulation, not a “natural” narrative.
Contraindications
A complete list must match the exact authorized product. For experimental materials without verified human labeling, a complete contraindication set is not established here. No list does not mean safety.
Interactions
Separate documented interaction, pharmacologic plausibility and unknown interaction. Absence of a blend trial does not establish compatibility.
Studies and trials
Selected studies
PMID40920401 · Randomized controlled trial
Pregnant participants with PCOS.
Oral with folate; folate control.
No significant reduction in the composite complication outcome.
Trial product/population; does not authenticate supplier material or permit simple indirect comparisons.
n = 464
Trials attributed in the package
No trials are attributed in this record.
Trial registration does not establish efficacy or validate commercial material.
Query candidates; attribution pending
Inositol · 195 unfiltered query results, not authenticated trials
Query verification: October 16, 2026
Exact phrase intervention query; first three most recently updated records, not exhaustive. Aliases may be missed and heterogeneous products may appear. The total is the unfiltered registry query count, not authenticated trials. Source-integrity holds are excluded from ordinary listings.
View trial registry queryNCT07770711 · Inositol and Metformin Administration in Mediterranean Diet and Low-Carbohydrate Diets in Women With PCOSRegistry status: RecruitingLast update posted: October 16, 2026Query verification: October 16, 2026
NCT07873294 · Letrozole Versus Letrozole and InositolRegistry status: CompletedLast update posted: October 14, 2026Query verification: October 16, 2026
NCT06800170 · Treatment of Menstrual Cycle Alterations in AdolescentsRegistry status: CompletedLast update posted: October 9, 2026Query verification: October 16, 2026
Source issues and references
References include queries and bibliographic handbook attributions; not all are clinical studies. Human review remains pending.
- PC-INOSITOL
PubChem myo-inositol (CID 892)
October 16, 2026
- PMID40920401
van der Wel AWT, Frank CMC, Bout-Rebel R, Duijnhoven RG, van Bree BE, Valkenburg O, Al-Nasiry S, van Oppenraaij RHF, Vogelvang TE, Westerhuis MEMH, van de Nieuwenhof HP, Gielen SCJP, Bandell ML, Bekker MN, Wouters MGAJ, Mijatovic V, Franx A, Lambalk CB, Broekmans FJM, de Weerd S, Gerards JMH, Baalman JH, van Disseldorp J, Langenveld J, Gunning MN, Frederix GWJ, Painter RC, Fauser BCJM, Laven JSE, van Rijn BB.
October 16, 2026
- SEARCH-PUBMED-inositol
October 16, 2026